image credit- shutterstock
Known for making innovative products catering to the gut microbiome, India’s first microbiome company, Bengaluru-based Leucine Rich Bio, has raised an undisclosed amount in a pre-series A round of funding.
The investment comes close to the heel of the company inaugurating a microbiome-focused gut health clinic in the heart of Bengaluru and exporting its products to the Philippines. The funding was spearheaded by prominent doctors including gastroenterologists and oncologists and biotech entrepreneurs.
The company raised its pre-seed funding worth Rs 2.3 crore in 2017. Besides the Philippines, Leucine Rich Bio has been exporting its products to Thailand since 2022. So far, the company has exported products worth more than Rs 18,00,000.
Commenting on the investment, Kumar Sankaran, CEO of Leucine Rich Bio, stated, "With this support, we are poised to take significant strides in our mission to harness the power of the microbiome to combat various chronic diseases and cancer."
The funds will be primarily utilised for marketing and development of new products. This investment will help the company in building its product portfolio and enhancing its R&D prowess. The company witnessed 20% year-on-year growth in 2022-23, while the quarter-on-quarter growth was 30% in quarter 2 of the financial year 2023-24.
Besides the popularity of its main product BugSpeaks, the company has seen an uptick in Rychbiome Indus’ demand by 101% in the period 2022-23 vs 2021-22.
